Zevra Therapeutics (NASDAQ:ZVRA) Insider Sells $40,026.39 in Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) insider Adrian Quartel sold 4,533 shares of Zevra Therapeutics stock in a transaction dated Friday, January 30th. The stock was sold at an average price of $8.83, for a total value of $40,026.39. Following the completion of the sale, the insider directly owned 9,723 shares of the company’s stock, valued at approximately $85,854.09. This trade represents a 31.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Zevra Therapeutics Stock Performance

Zevra Therapeutics stock traded up $0.36 during midday trading on Monday, reaching $9.36. The stock had a trading volume of 1,074,144 shares, compared to its average volume of 1,039,668. The firm has a market capitalization of $526.97 million, a PE ratio of 19.91 and a beta of 0.99. Zevra Therapeutics, Inc. has a 12 month low of $6.19 and a 12 month high of $13.16. The company has a quick ratio of 8.57, a current ratio of 8.62 and a debt-to-equity ratio of 0.46. The firm’s 50-day moving average price is $8.64 and its 200 day moving average price is $9.45.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Wednesday, November 5th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.03. Zevra Therapeutics had a net margin of 41.93% and a negative return on equity of 51.40%. The firm had revenue of $26.06 million during the quarter, compared to the consensus estimate of $26.64 million. As a group, research analysts predict that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zevra Therapeutics

Several hedge funds have recently bought and sold shares of ZVRA. UBS Group AG grew its stake in Zevra Therapeutics by 30.9% in the 4th quarter. UBS Group AG now owns 285,488 shares of the company’s stock worth $2,558,000 after buying an additional 67,392 shares in the last quarter. Sanctuary Advisors LLC lifted its holdings in shares of Zevra Therapeutics by 18.0% during the 4th quarter. Sanctuary Advisors LLC now owns 34,461 shares of the company’s stock worth $309,000 after acquiring an additional 5,247 shares during the last quarter. Retirement Planning Co of New England Inc. grew its position in Zevra Therapeutics by 10.4% in the fourth quarter. Retirement Planning Co of New England Inc. now owns 662,976 shares of the company’s stock worth $5,940,000 after acquiring an additional 62,206 shares in the last quarter. Stratos Wealth Partners LTD. grew its position in Zevra Therapeutics by 78.6% in the fourth quarter. Stratos Wealth Partners LTD. now owns 409,000 shares of the company’s stock worth $3,665,000 after acquiring an additional 180,000 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. purchased a new stake in Zevra Therapeutics during the fourth quarter valued at about $1,251,000. 35.03% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ZVRA has been the subject of a number of analyst reports. Cantor Fitzgerald cut their price target on Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. HC Wainwright set a $26.00 target price on Zevra Therapeutics in a report on Tuesday, December 30th. Weiss Ratings reissued a “sell (d+)” rating on shares of Zevra Therapeutics in a report on Friday, January 9th. Finally, Canaccord Genuity Group cut their price objective on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, November 6th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $22.80.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.